Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

Inclusion criteria

* Histologically confirmed B-cell lymphoma * Eligible subtypes: * Intermediate or high-grade non-Hodgkin's lymphoma (NHL), defined as follicular large cell, mantle cell, diffuse mixed cell, diffuse large cell and variants, Burkitt or Burkitt-like, or unclassifiable aggressive histologies * Body cavity-based lymphoma or primary effusion lymphoma * Evidence of HIV infection * Received at least 1 prior systemic chemotherapy regimen with failure to respond or relapse after completion of first-line therapy, including one of the following doxorubicin-based combinations: * Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) * Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) * Etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) * Evaluable disease outside of prior radiation port * No CNS parenchymal or leptomeningeal involvement * No primary CNS NHL * No HTLV-1-associated leukemia or lymphoma * Performance status - Karnofsky 70-100% * At least 12 weeks * Absolute granulocyte count at least 1,000/mm3 * Platelet count at least 75,000/mm3 * Hemoglobin at least 8.0 g/dL * Bilirubin no greater than 1.5 mg/dL (unless concurrently on indinavir) * SGOT and SGPT less than 3 times upper limit of normal * Creatinine no greater than 1.5 mg/dL * Creatinine clearance at least 50 mL/min * No history of cardiac disease * LVEF at least 45% by radionuclide ventriculography * No symptomatic congestive heart failure * No active angina pectoris * No uncontrolled hypertension * No history of symptomatic pulmonary disease * Corrected DLCO more than 50% predicted * No severe chronic obstructive lung disease * No symptomatic restrictive lung disease * Recurrent controllable infection (e.g., thrush) on chronic suppressive therapy allowed * No active uncontrolled infection * No active significant opportunistic infection (e.g., acute Pneumocystis pneumonia, cytomegalovirus retinitis on induction or maintenance therapy, acute toxoplasmosis) * No grade 2 or greater peripheral neuropathy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * At least 24 hours since prior transfusion * At least 24 hours since prior colony-stimulating factor therapy * No concurrent prophylactic filgrastim (G-CSF) * See Disease Characteristics * No concurrent hydroxyurea * See Disease Characteristics * At least 4 weeks since prior large-field radiotherapy * At least 3 weeks since prior anticancer therapy and recovered * Must be receiving stable antiretroviral regimen of at least 4 weeks duration